Journal article
Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network
Clinical infectious diseases, Vol.46(11), pp.1738-1740
06/01/2008
DOI: 10.1086/587989
PMID: 18419421
Abstract
We present the results of a nationwide survey of infectious disease consultants to identify mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor compounds and other novel targeted therapies. Nontuberculous mycobacterial infections, histoplasmosis, and invasive Staphylococcus aureus infection were all reported more frequently than was tuberculosis disease in this context.
Details
- Title: Subtitle
- Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network
- Creators
- Kevin L Winthrop - Oregon Health & Sciences University, Portland 97239, USA. Winthrop@ohsu.eduS YamashitaS E BeekmannP M PolgreenInfectious Diseases Society of America Emerging Infections Network
- Resource Type
- Journal article
- Publication Details
- Clinical infectious diseases, Vol.46(11), pp.1738-1740
- DOI
- 10.1086/587989
- PMID
- 18419421
- NLM abbreviation
- Clin Infect Dis
- ISSN
- 1058-4838
- eISSN
- 1537-6591
- Grant note
- 5 U50 CI000358 / NCPDCID CDC HHS
- Language
- English
- Date published
- 06/01/2008
- Academic Unit
- Infectious Diseases; Epidemiology; Injury Prevention Research Center; Internal Medicine
- Record Identifier
- 9984094210502771
Metrics
24 Record Views